What Nobelpharma does

Nobelpharma Co., Ltd. (ノーベルファーマ株式会社) is a privately held Japanese specialty pharmaceutical company founded in 2003 and headquartered in Tokyo's Chuo-ku district. The company's stated mission is to develop and provide pharmaceutical products and medical devices for rare diseases and unmet medical needs that larger pharmaceutical companies have overlooked. Its portfolio consists of approximately 15 approved prescription products spanning rare neurological conditions (neonatal convulsions, GNE myopathy, sleep disorders in neurodevelopmental disorders), rare pulmonary conditions (autoimmune pulmonary alveolar proteinosis, lymphangioleiomyomatosis, pleural effusion/pneumothorax), rare dermatological conditions (TSC skin lesions), rare women's health conditions (dysmenorrhea, endometriosis), rare neonatal conditions (apnea of prematurity), rare ENT conditions (spasmodic dysphonia, tympanic membrane perforation), and rare metabolic conditions (Wilson's disease, zinc deficiency). Key branded assets include Rapalimus (mTOR inhibitor in tablet and topical gel forms for TSC and LAM), Noverzin and Jintas (zinc-based therapies), Acenover (GNE myopathy), Salgran (APAP), and Melatobel (pediatric sleep disorders).

The company's underlying capability is pharmaceutical development and commercialization for orphan indications, rather than any specific platform technology. It operates a sales-led go-to-market model through a dedicated medical representative (MR) force targeting healthcare professionals, with disease-awareness portals (aendegenki.jp, nobelpark.jp, and condition-specific sub-sites) supporting physician and patient education. Products are distributed through major Japanese pharmaceutical wholesalers including Medipal Holdings, Mediceo, Aska Seiyaku, Atoru, Ebalus, Yoniyaku, Nakazawa-Yakugyo, and Higashishichi, and dispensed via prescription through hospitals and pharmacies.

Nobelpharma generates revenue primarily through prescription pharmaceutical sales in Japan, with prices set by the national health insurance reimbursement system and not publicly disclosed. The company has begun selective international commercialization, exporting products to China (Noverzin launched June 2026) and operating a wholly-owned US subsidiary (Nobelpharma America LLC) for cross-border operations and data-sharing. The company's CEO is Hitoshi Shiomura (塩村仁), and it has a headcount of 251-500 employees. Customer segments are healthcare professionals who prescribe orphan-disease therapies and the rare-disease patient populations they treat.

Name

Nobelpharma

Legal name

ノーベルファーマ株式会社 (Nobelpharma Co., Ltd.)

Website

https://nobelpharma.co.jp

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

251–500 employees

Short description

Nobelpharma is a Japanese specialty pharmaceutical company that develops and commercializes orphan drugs for rare diseases and unmet medical needs, serving patients with conditions such as TSC, LAM, GNE myopathy, Wilson's disease, and APAP across Japan and select international markets including China.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Orphan Drugs)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Rare Dermatology Disorder Therapies (HLAIAIAM), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Rare Cardiovascular & Vascular Disorder Therapies (HLAIAIAH)

Keywords

• Orphan drug development
• Rare disease pharmaceuticals
• Unmet medical needs
• Specialty therapeutics
• Prescription medicines

Headquarters

HQ city

Shinkawa

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Prescription Pharmaceutical Products: Nobelpharma generates revenue through the sale of prescription pharmaceutical products primarily in Japan, focusing on orphan drugs and treatments for rare diseases with limited competition.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Nobelpharma researches, develops, and commercializes prescription pharmaceutical products targeting rare diseases and unmet medical needs, with a focus on orphan drugs across therapeutic areas such as oncology, neurology, dermatology, and rare genetic conditions. The company sells its medicines through pharmaceutical wholesalers to hospitals, clinics, and pharmacies in Japan and selected international markets.

Product overview

Nobelpharma is a Japanese pharmaceutical company focused on developing and providing medications for rare diseases and unmet medical needs. The company offers a portfolio of specialized pharmaceutical products across multiple therapeutic areas including: zinc deficiency treatments (Noverzin, Jintas), respiratory/pulmonary conditions (Salgran for APAP, Unitalc for pleural effusion, Rapalimus for LAM/TSC), neurological conditions (Noverbar/Fostoin for seizures, Melatobel for sleep disorders, Titan Bridge for voice disorders), dermatology (Rapalimus Gel for skin lesions), women's health (Lunabell, Jemina for dysmenorrhea/endometriosis), neonatal care (Respier for apnea of prematurity), ENT conditions (Ritympa for tympanic membrane), and rare genetic diseases (Acenover for GNE myopathy). Nobelpharma positions itself as addressing diseases that are often overlooked by other pharmaceutical companies, providing treatments for conditions such as tuberous sclerosis complex, lymphangioleiomyomatosis, and various orphan diseases.

Differentiator

Problem solved

Functional benefit

Brands

• NobelPark: Product information portal for healthcare professionals featuring product details and medical information.

Products and services

• ノベルジン®錠25mg/50mg (Noverzin Tablet 25mg/50mg) Zinc deficiency treatment agent also used for Wilson's disease (hepatolenticular degeneration); available in 25mg and 50mg tablet formulations for healthcare providers.
• ジンタス®25㎎錠 (Jintas 25mg Tablet) Zinc deficiency treatment agent indicated for hypozincemia; available as a 25mg tablet for prescription use.
• ラパリムス®錠 (Rapalimus Tablet) mTOR inhibitor (sirolimus-based) tablet indicated for lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC) associated conditions in adults.
• ラパリムス®ゲル (Rapalimus Gel) Topical sirolimus gel formulation for tuberous sclerosis complex (TSC) associated skin lesions (facial angiofibromas).
• ルナベル®配合錠LD (Lunabell LD Tablet) Low-dose combined oral contraceptive tablet (ethinylestradiol/norethisterone) used for the treatment of dysmenorrhea and endometriosis.
• ジェミーナ (Jemina) Low-dose combined oral contraceptive tablet indicated for the treatment of dysmenorrhea.
• レスピア (Respier) Caffeine citrate formulation indicated for primary apnea of prematurity (immature infant apnea) in premature and low birth weight infants.
• チタンブリッジ (Titan Bridge) Medical device indicated for adductor type spasmodic dysphonia (ADSD), a voice disorder where the voice becomes stuck or interrupted when attempting to speak.
• リティンパ (Ritympa) Regenerative medicine product indicated for tympanic membrane perforation (persistent eardrum perforation).
• ユニタルク (Unitalc) Talc-based medical product for the prevention of malignant pleural fluid re-accumulation or recurrent refractory secondary pneumothorax where surgical treatment is difficult.
• ノーベルバール (Noverbar) Phenobarbital anticonvulsant indicated for the treatment of neonatal convulsions.
• ホストイン (Fostoin)

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered minor and core.

• NovartisminorOthers · 23 April 2026Both companies are identified as prominent players in the global tuberous sclerosis complex (TSC) market according to Research and Markets analysis. Nobelpharma is mentioned alongside Novartis in market research reports covering TSC treatments.
• Jazz PharmaceuticalsminorOthers · 23 April 2026Both companies are identified as prominent players in the global tuberous sclerosis complex (TSC) market according to Research and Markets analysis. Nobelpharma is mentioned alongside Jazz Pharmaceuticals in market research reports covering TSC treatments.
• Medipal HoldingscoreChannel Partner/ Reseller/ DistributorMajor pharmaceutical wholesale distribution partner in Japan. Medipal Holdings distributes Nobelpharma products to medical institutions and pharmacies throughout Japan as part of the company's distribution network.
• MediceocoreChannel Partner/ Reseller/ DistributorPharmaceutical wholesale distribution partner. Mediceo distributes Nobelpharma products as part of the pharmaceutical distribution network in Japan.
• Aska SeiyakucoreChannel Partner/ Reseller/ DistributorPharmaceutical wholesale distribution partner and joint use partner for medical representative information sharing and distribution optimization.
• Nobelpharma America LLCcoreOthersWholly-owned subsidiary of Nobelpharma Co., Ltd. located in the United States. Engages in joint use of customer data with the parent company for pharmaceutical business operations.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Jazz Pharmaceuticals: Global specialty pharmaceutical company with established rare disease franchises, explicitly identified alongside Nobelpharma as a prominent player in the global TSC market. Directly comparable in orphan-disease strategy and therapeutic-area focus.
• Nippon Shinyaku: Japanese specialty pharmaceutical company with a strong rare-disease focus, including treatments for genetic and orphan indications. Directly comparable as a Japan-based specialty pharma addressing unmet medical needs in similar therapeutic areas.
• Taiho Pharmaceutical: Japanese specialty pharmaceutical company with oncology and rare-disease franchises. Comparable as a mid-to-large Japanese specialty pharma that has successfully built niche specialty franchises outside the mainstream pharma model.
• Mochida Pharmaceutical: Japanese specialty pharmaceutical company focused on niche therapeutic areas including rare diseases and specialty indications. Comparable as a Japanese mid-sized specialty pharma with orphan-disease products.

Broad incumbents

• Recordati Rare Diseases: Specialty pharmaceutical group with a dedicated rare-disease business unit marketing treatments for orphan indications globally. Comparable as a specialty pharma with orphan-disease franchise and similar European/global commercial profile.
• Alexion (AstraZeneca Rare Disease): Rare-disease specialty pharmaceutical unit of AstraZeneca, focused on complement-mediated and other orphan conditions. Comparable as a rare-disease-focused commercial franchise operating within a larger parent — similar orphan-drug commercial model to Nobelpharma's.
• BioMarin Pharmaceutical: Global rare-disease specialty pharmaceutical company marketing therapies across genetic and orphan indications. Comparable business model of developing and commercializing drugs for small populations with high unmet need.
• Vertex Pharmaceuticals: Global specialty pharmaceutical company whose strategy centers on rare and serious diseases (CF, sickle cell, pain). Comparable as a rare-disease-focused commercial-stage pharma, though materially larger and globally commercialized.
• Novartis: Identified alongside Nobelpharma as a prominent global TSC market player through its Afinitor franchise. A large diversified pharma incumbent with significant rare-disease presence that overlaps with Nobelpharma's core therapeutic areas.

Emerging players

• Ultragenyx Pharmaceutical: Clinical and commercial-stage biopharmaceutical company focused exclusively on rare and ultra-rare genetic diseases. Comparable as a rare-disease specialist with overlapping therapeutic approaches to genetic and metabolic orphan conditions.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/watch?v=Uy3xx-uXBm0

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nobelpharma